Skip to main content
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1986 Jun;70(6):471–473. doi: 10.1136/bjo.70.6.471

Ocular toxicity of Anandron in patients treated for prostatic cancer.

C Harnois, M Malenfant, A Dupont, F Labrie
PMCID: PMC1041045  PMID: 3718913

Abstract

Approximately 65% of patients with prostatic cancer treated by the combination therapy using a gonadorelin (LHRH) agonist or orchidectomy in association with the antiandrogen Anandron complained of a delay in recovering vision after bright illumination (sun, television, bright light). Detailed ophthalmological examination revealed an increase in the photostress recovery time to an average of 9 min, while the upper limit of normal is 1 min 20 s. When treatment was changed from Anandron to the other pure antiandrogen flutamide, the value of the photostress recovery time markedly decreased and the visual symptoms rapidly disappeared. Since uninterrupted administration of the antiandrogen is of the outmost importance for the successful therapy of prostatic cancer, the availability of a compound such as flutamide that has no side effect other than those due to hypoandrogenicity should greatly facilitate compliance by the patients and the success of the treatment.

Full text

PDF
471

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown K. T. The eclectroretinogram: its components and their origins. Vision Res. 1968 Jun;8(6):633–677. doi: 10.1016/0042-6989(68)90041-2. [DOI] [PubMed] [Google Scholar]
  2. FORSIUS H., ERIKSSON A. W., KRAUSE U. THE DAZZLING TEST IN DISEASES OF THE RETINA. Acta Ophthalmol (Copenh) 1964;42:55–63. doi: 10.1111/j.1755-3768.1964.tb07848.x. [DOI] [PubMed] [Google Scholar]
  3. Frost-Larsen K., Larsen H. W., Simonsen S. E. Oscillatory potential and nyctometry in insulin-dependent diabetics. Acta Ophthalmol (Copenh) 1980 Dec;58(6):879–888. doi: 10.1111/j.1755-3768.1980.tb08313.x. [DOI] [PubMed] [Google Scholar]
  4. Glaser J. S., Savino P. J., Sumers K. D., McDonald S. A., Knighton R. W. The photostress recovery test in the clinical assessment of visual function. Am J Ophthalmol. 1977 Feb;83(2):255–260. doi: 10.1016/0002-9394(77)90624-9. [DOI] [PubMed] [Google Scholar]
  5. Labrie F., Belanger A., Dupont A., Emond J., Lacoursiere Y., Monfette G. Combined treatment with LHRH agonist and pure antiandrogen in advanced carcinoma of prostate. Lancet. 1984 Nov 10;2(8411):1090–1090. doi: 10.1016/s0140-6736(84)91521-6. [DOI] [PubMed] [Google Scholar]
  6. Labrie F., Dupont A., Belanger A. Complete androgen blockade for the treatment of prostate cancer. Important Adv Oncol. 1985:193–217. [PubMed] [Google Scholar]
  7. Resnick M. I., Grayhack J. T. Treatment of stage IV carcinoma of the prostate. Urol Clin North Am. 1975 Feb;2(1):141–161. [PubMed] [Google Scholar]
  8. Severin S. L., Tour R. L., Kershaw R. H. Macular function and the photostress test 1. Arch Ophthalmol. 1967 Jan;77(1):2–7. doi: 10.1001/archopht.1967.00980020004002. [DOI] [PubMed] [Google Scholar]
  9. Tiburtius H. F. Der Blendungstest in Klinik und Praxis. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1969;178(4):333–348. doi: 10.1007/BF00410480. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES